About Cerebrolysin
Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity
Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.
Cerebrolysin Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Investigational
Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
7 sources cited · 7 moderate
1 RCT · 1 Meta-analysis · 5 Cohorts
Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the Helix pomatia-Snail Model of Learning and Memory.
Biomolecules · 2026
# Research Summary This study demonstrated that Cerebrolysin decreased kynurenic acid (KYNA) formation in snail liver tissue and reversed learning impairment caused by elevated KYNA levels in a snail memory model. Researchers observed that by reducing KYNA synthesis, Cerebrolysin restored learning-related behaviors that had been suppressed by L-kynurenine administration, suggesting a potential mechanism by which the compound may support cognitive function.
Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice.
J Alzheimers Dis · 2026
# Summary This article is a retraction notice, meaning the original research paper has been withdrawn from the scientific record and is no longer considered valid. Therefore, no primary finding can be accurately summarized, as the study's results are no longer considered reliable or publishable scientific evidence.
Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles.
Neurochem Res · 2026
This is a **retraction notice**, not a summary of research findings. The document does not contain an abstract with results—it only lists author information and the retracted paper's title. The retracted study had investigated whether Cerebrolysin could mitigate neuropathic pain and spinal cord damage in models of nanoparticle toxicity, but the research has been formally withdrawn and is no longer considered valid scientific evidence.
Show 4 more sources ↓
Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis.
Asian J Neurosurg · 2026
# Summary Research found that adults with moderate traumatic brain injury and nonoperative intracerebral hemorrhage who received Cerebrolysin in addition to standard care demonstrated significantly greater functional improvement on cognitive recovery measures, higher functional independence scores, and improved 6-month survival rates compared to those receiving standard care alone, with no increase in adverse events. This study demonstrated the potential neuroprotective benefit of Cerebrolysin in this patient population, though the researchers acknowledged that the study design limits definitive causal conclusions and called for randomized controlled trials to confirm these findings.
Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability.
Cells · 2026
# Summary Research found that exosomes released by cerebral endothelial cells treated with Cerebrolysin (Cerebro-Exos) successfully restored the integrity of damaged endothelial cells that had been impaired by fibrin or tissue plasminogen activator (tPA). This therapeutic effect appeared to work by altering protein profiles in dysfunctional cells, particularly by reducing inflammation and coagulation-related proteins while increasing tight junction and metabolic proteins.
Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
Research in a 3-year prospective comparative study found that annual courses of intravenous Cerebrolysin reduced the rate of cognitive deficit progression and conversion from amnestic mild cognitive impairment to dementia compared with untreated controls in elderly patients, suggesting a disease-modifying effect for repeated annual neuroprotective intervention.
Cerebrolysin for vascular dementia
Cochrane Database of Systematic Reviews · 2019
This Cochrane systematic review of 6 randomized controlled trials (597 participants) found that intravenous Cerebrolysin improved cognition and global function in people with vascular dementia compared with placebo with no increase in adverse effects, though all included evidence was rated very low quality due to high risk of bias and heterogeneity, and no new studies had been published since the previous 2013 review.
Cerebrolysin Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Cerebrolysin — Providers & Availability
30 providersClinics
10 providersApex Health & Wellness
United StatesView →Center for Advanced Urology
United StatesView →Dr. Erica Oberg
United StatesView →Florida Regenerative
United StatesView →Hormone & Peptide Therapy Greenville SC
United StatesView →Protocol Health
United StatesView →Functional Medicine Las Vegas
United StatesView →SYNC Life
United StatesView →IV Vitamin Therapy San Diego
United StatesView →Meeting Point Health
United StatesView →
Stay updated on verified Cerebrolysin providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Cerebrolysin
Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways.
neuroprotection, neuroplasticity, memory improvement, cognitive recovery.
Research on Cerebrolysin primarily documents effects related to neuroprotection and neuroplasticity and memory improvement and cognitive recovery. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Cerebrolysin include epilepsy, renal failure, porcine protein allergy. This is educational information only — consult a qualified healthcare professional before use.
30 providers in the directory currently offer Cerebrolysin.
# Research Summary This study demonstrated that Cerebrolysin decreased kynurenic acid (KYNA) formation in snail liver tissue and reversed learning impairment caused by elevated KYNA levels in a snail memory model. Researchers observed that by reducing KYNA synthesis, Cerebrolysin restored learning-related behaviors that had been suppressed by L-kynurenine administration, suggesting a potential mechanism by which the compound may support cognitive function.